Citations

Institution: Mayo Clinic Clear

Showing 10 of 108081 citations.

Benign Prostatic Hyperplasia
Leedahl, David D. , Vo, Phil H., Maxson, Pamela M., Lovely, Jenna K.

Journal of Pharmacy Practice | July 14, 2012 | Volume: 26 | Issue: 1 | Pages: 52-58

10.1177/0897190012451913 | PMID 22797835 Get It

This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha 1 receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent evidence suggests that Holmium laser enucleation of the prostate may have similar efficacy with less risk of complications and with decreased catheterization time. Prostatic urological operations may have perioperative complications, including urethral bleeding, acute urinary retention, urinary tract infection, urge incontinence, and venous thromboembolism. Pharmacist recommendations for the appropriate use of laxatives, antibiotics, anticoagulation, and urinary antispasmodics are key components of perioperative management. Surgical interventions improve symptoms but may have complications, providing the pharmacist an opportunity to improve perioperative care.
A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Bender, Julia Glade , Blaney, Susan M. , Baruchel, Sylvain , Ahern, Charlotte H., Ingle, Ashish M., Chen, Alice P. , Weigel, Brenda J. , Adamson, Peter C. , Borinstein, Scott C. , Reid, Joel M. , Yamashiro, Darrell J. , Park, Julie R. , Glade-Bender, Julia

Clinical Cancer Research | July 13, 2012 | Volume: 18 | Issue: 18 | Pages: 5081-5089

10.1158/1078-0432.ccr-12-0078 | PMID 22791883 Get It

Abstract Purpose: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept. Experimental Design: Cohorts of three to six children with refractory solid tumors received aflibercept intravenously over 60 minutes every 14 days, at 2.0, 2.5, or 3.0 mg/kg/dose. PK sampling and analysis of peripheral blood biomarkers were conducted with the initial dose. Results: Twenty-one eligible patients were enrolled; 18 were fully evaluable for toxicity. One of six patients receiving 2.0 mg/kg/dose developed dose-limiting intratumoral hemorrhage and two of six receiving 3.0 mg/kg/dose developed either dose-limiting tumor pain or tissue necrosis. None of the six patients receiving 2.5 mg/kg/dose developed DLTs, defining this as the MTD. The most common non-DLTs were hypertension and fatigue. Three patients with hepatocellular carcinoma, hepatoblastoma and clear cell sarcoma had stable disease for >13 weeks. At the MTD, the ratio of free-to-bound aflibercept serum concentration was 2.10 on day 8 but only 0.44 by day 15. A rapid decrease in VEGF (P < 0.05) and increase in placental growth factor (PlGF; P < 0.05) from baseline was observed in response to aflibercept by day 2. Conclusions: The aflibercept MTD in children of 2.5 mg/kg/dose every 14 days is lower than the adult recommended dose of 4.0 mg/kg. This dose achieves, but does not sustain, free aflibercept concentrations in excess of bound. Tumor pain and hemorrhage may be evidence of antitumor activity but were dose-limiting. Clin Cancer Res; 18(18); 5081–9. ©2012 AACR.
Repeat Retail Clinic Visits: Impact of Insurance Coverage and Age of Patient
Angstman, Kurt B. , Bernard, Matthew , Rohrer, James E. , Garrison, Gregory M. , MacLaughlin, Kathy L.

Population Health Management | July 13, 2012 | Volume: 15 | Issue: 6 | Pages: 358-361

10.1089/pop.2011.0088 | PMID 22788953 Get It

As retail clinics provide a less costly alternative for health care, it would be reasonable to expect an increase in multiple (repeat) retail visits by those patients who may have expenses for receiving primary care. If costs were not a significant factor, then repeat visits should not be significantly different between these patients and those with coverage for primary care visits. The hypothesis for this study was that patients with the potential for out-of-pocket expenses would have a higher frequency of repeat retail clinic visits within 180 days compared to those with primary care coverage. A retrospective chart review was conducted of 5703 patients utilizing a retail clinic in Rochester, Minnesota from January 1, 2009 through June 30, 2009. The first visit to the retail clinic was considered the index visit and the chart was reviewed for repeat retail clinic visits within the next 180 days. Using a multiple logistic regression model, the odds of a pediatric patient ( N =2344) having a repeat retail visit within 180 days of the index visit were not significantly impacted by insurance coverage ( P =0.4209). Of the 3359 adult patients, those with unknown coverage had a 25.6% higher odds ratio of repeat retail clinic visits than those with insurance coverage (odds ratio 1.2557, confidence interval 1.0421–1.5131). This study suggested that when cost is an issue, the adult patient may favor retail clinics for episodic, low-acuity health care. In contrast, the pediatric population did not, suggesting that other factors, such as convenience, may play more of a role in the choice of episodic health care for this age group. ( Population Health Management 2012;15:358–361)
Large-scale replication and heterogeneity in Parkinson disease genetic loci
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Broeckhoven, Christine Van , Bozi, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Lesage, Suzanne , Lill, Christina M. , Lin, Juei-Jueng, Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Theuns, Jessie , Tan, Eng-King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Boyle, R.S, Sellbach, A, Siebert, G., Pickut, Barbara , Engelborghs, Sebastiaan , Meeus, Bram, Deyn, Peter Paul De, Cras, Patrick , Agid, Yves, Anheim, Mathieu , Bonnet, A-M, Broussolle, E. , Corvol, Jean‐Christophe , Destée, A., Durif, F., Lesage, Suzanne , Lohmann, Ebba , Pollak, Pierre, Rascol, Olivier , Tison, François , Viallet, François, Amouyel, Philippe , Loriot, Marie‐Anne , Mutez, Eugénie , Duflot, Aurélie , Legendre, Jean-Philippe, Waucquier, Nawal, Schulte, Claudia , Klein, Christine , Djarmati, Ana, Hagenah, Johann, Lohmann, Katja , Hilker, Rüdiger, Loo, Simone van de, Tsimourtou, Vaïa, Ralli, Styliani, Kountra, Persa, Patramani, Gianna, Vogiatzi, Cristina, Hattori, Nobutaka, Yoshino, Hiroyo , Li, Yuanzhe, Imamichi, Yoko, Gibson, J. Mark , Ialongo, Tàmara, Brighina, Laura , Corradi, B., Piolti, Roberto, Tarantino, Patrizia, Kłodowska-Duda, Gabriela, Boczarska‐Jedynak, Magdalena , Tan, Eng King, Olson, Lars, Westerlund, Marie, Sydow, Olof , Puschmann, Andreas , Lin, J-J , J, Eric Ahlskog, Lesnick, Timothy G. , Rocca, Walter A. , Checkoway, Harvey , Westenberger, Ana , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Mok, Vincent , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , O’Sullivan, John D. , Sutherland, Greg T. , Dissanayaka, Nadeeka N. , Borg, Michael , Damier, Philippe , Dürr, Alexandra , Tranchant, Christine , Vidailhet, Marie , Tzourio, Christophe , Rieß, Olaf , Berg, Daniela , Dardiotis, Efthimios , Funayama, Manabu , Valente, Enza Maria , Ferraris, Alessandro , Dallapiccola, Bruno , Annesi, Ferdinanda , Belin, Andrea Carmine , Olson, Lars, Galter, Dagmar , Nilsson, Christer C. , Andrade, Mariza de , Lang, Anthony E , Ross, Owen A , Puschmann, Andreas , Klein, Christine , Amouyel, Philippe , Corvol, Jean-Christophe , Mutez, Eugénie , Schulte, Claudia , Brice, Alexis

Neurology | July 12, 2012 | Volume: 79 | Issue: 7 | Pages: 659-667

10.1212/wnl.0b013e318264e353 | PMID 22786590 Get It

Videoscopic Left Cardiac Sympathetic Denervation for Patients With Recurrent Ventricular Fibrillation/Malignant Ventricular Arrhythmia Syndromes Besides Congenital Long-QT Syndrome
Coleman, Mira A., Bos, J. Martijn , Johnson, Jonathan N. , Owen, Heidi J., Deschamps, Claude, Moir, Christopher R. , Ackerman, Michael J. , Bos, Johan M

Circulation: Arrhythmia and Electrophysiology | July 12, 2012 | Volume: 5 | Issue: 4 | Pages: 782-788

10.1161/circep.112.971754 | PMID 22787014 Get It

Background— Treatment options for patients with recurrent ventricular arrhythmias refractory to pharmacotherapy and ablation are minimal. Although left cardiac sympathetic denervation (LCSD) is well established in long-QT syndrome, its role in non–long-QT syndrome arrhythmogenic channelopathies and cardiomyopathies is less clear. Here, we report our single-center experience in performing LCSD in this setting. Methods and Results— In this institutional review board–approved study, we retrospectively reviewed the electronic medical records of all patients (N=91) who had videoscopic LCSD at our institution from 2005 to 2011. Data were analyzed for the subset (n=27) who were denervated for an underlying diagnosis other than autosomal dominant or sporadic long-QT syndrome. The spectrum of arrhythmogenic disease included catecholaminergic polymorphic ventricular tachycardia (n=13), Jervell and Lange-Nielsen syndrome (n=5), idiopathic ventricular fibrillation (n=4), left ventricular noncompaction (n=2), hypertrophic cardiomyopathy (n=1), ischemic cardiomyopathy (n=1), and arrhythmogenic right ventricular cardiomyopathy (n=1). Five patients had LCSD because of high-risk assessment and β-blocker intolerance, none of whom had a sentinel breakthrough cardiac event at early follow-up. Among the remaining 22 previously symptomatic patients who had LCSD as secondary prevention, all had an attenuation in cardiac events, with 18 having no breakthrough cardiac events so far and 4 having experienced ≥1 post-LCSD breakthrough cardiac event. Conclusions— LCSD may represent a substrate-independent antifibrillatory treatment option for patients with life-threatening ventricular arrhythmia syndromes other than long-QT syndrome. The early follow-up seems promising, with a marked reduction in the frequency of cardiac events postdenervation.
Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression
Stallings‐Mann, Melody , Waldmann, Jens, Miller, Erin , Gauthier, Mona L., Visscher, Daniel W., Downey, Gregory P. , Radisky, Evette S. , Fields, Alan P. , Zhang, Ying , Radisky, Derek C. , Radisky, Evette S

Science Translational Medicine | July 11, 2012 | Volume: 4 | Issue: 142 | Pages: No page available

10.1126/scitranslmed.3004062 | PMID 22786680 Get It

Rac1b mediates the matrix metalloproteinase–induced epithelial-mesenchymal transition in lung adenocarcinoma and is a potential therapeutic target in early-stage lung cancer.
High-Flow Nasal Cannula Therapy in Do-Not-Intubate Patients With Hypoxemic Respiratory Distress
Peters, Steve G. , Holets, Steven R, Gay, Peter C.

Respiratory Care | July 11, 2012 | Volume: 58 | Issue: 4 | Pages: 597-600

10.4187/respcare.01887 | PMID 22781059 Get It

A Drug-Like Antagonist Inhibits Thyrotropin Receptor–Mediated Stimulation of cAMP Production in Graves' Orbital Fibroblasts
Neumann, Susanne , Pope, Arthur L., Geras‐Raaka, Elizabeth, Raaka, Bruce M., Bahn, Rebecca S. , Gershengorn, Marvin C.

Thyroid | July 11, 2012 | Volume: 22 | Issue: 8 | Pages: 839-843

10.1089/thy.2011.0520 | PMID 22784331 Get It

Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Mohabbat, Arya B. , Sandborn, William J. , Loftus, Edward V. , Wiesner, Russell H., Bruining, David H. , Loftus, Edward V

Alimentary Pharmacology & Therapeutics | July 11, 2012 | Volume: 36 | Issue: 6 | Pages: 569-574

10.1111/j.1365-2036.2012.05217.x | PMID 22779779 Get It

SummaryBackgroundUlcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post‐transplantation immunosuppressive therapy.AimTo evaluate the efficacy and safety of anti‐tumour necrosis factor (anti‐TNF) agents for the management of IBD following OLT.MethodsWe reviewed the records of patients with a diagnosis of IBD who underwent OLT at Mayo Clinic Rochester between 1985 and 2009. Patients were included if they had received anti‐TNF therapy post‐OLT. Clinical response was defined as a physician's assessment of improvement after 12 weeks of anti‐TNF usage, and mucosal healing was defined as the absence of ulcerations on follow‐up endoscopy.ResultsThe median age of the eight study patients was 42.0 years and 37.5% were female patients. All had been diagnosed with IBD prior to OLT (UC in three and Crohn's disease in five). Indication for OLT was cirrhotic stage primary sclerosing cholangitis (PSC), and three concomitantly had cholangiocarcinoma. Clinical response was demonstrated in seven of eight patients (87.5%) and mucosal healing was demonstrated in three of seven (42.9%). Four infections (oral candidiasis, Clostridium difficile colitis, bacterial pneumonia and cryptosporidiosis) in three patients were reported. One patient developed an Epstein–Barr virus‐positive post‐transplant lympho‐proliferative disorder. One death occurred due to complications from recurrent PSC.ConclusionsStarting Anti‐TNF therapy following orthotopic liver transplantation appears to be a potential option for inflammatory bowel disease management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.
Reply to M. Bibas
Pardanani, Animesh , Tefferi, Ayalew

Journal of Clinical Oncology | July 10, 2012 | Volume: 30 | Issue: 24 | Pages: 3034-3034

10.1200/jco.2012.44.3176 Get It